Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Athira Pharma, Inc. (ATHA)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 30,820,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Athira Pharma is a late clinical-stage biopharmaceutical company. Co.'s primary candidate, fosgonimeton (ATH-1017), is a blood brain barrier-penetrating, small molecule hepatocyte growth factor (HGF)/MET positive modulator. The primary target indication is Alzheimer's disease (AD). Co.'s product candidate for its neuropsychiatric program is ATH-1020, which is a small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and to distribute to the central nervous system. Co. has several preclinical candidates for non-AD indications, including ATH-1019, which is being developed to address peripheral indications such as peripheral neuropathy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 605,686 685,698 2,157,060
Total Buy Value $0 $1,462,896 $1,705,913 $6,104,477
Total People Bought 0 1 2 6
Total Buy Transactions 0 3 6 13
Total Shares Sold 0 13,264 13,264 36,879
Total Sell Value $0 $38,598 $38,598 $102,919
Total People Sold 0 5 5 6
Total Sell Transactions 0 5 5 12
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 96
  Page 2 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Church Kevin Chief Scientific Officer   •       –      –    2023-01-05 4 S $2.91 $7,019 D/D (2,412) 80,256     -
   Gengos Andrew See Below   •       –      –    2023-01-04 4 A $0.00 $0 D/D 5,000 85,012     -
   Church Kevin Chief Scientific Officer   •       –      –    2023-01-04 4 A $0.00 $0 D/D 10,000 82,668     -
   Mileson Glenna Chief Financial Officer   •       –      –    2022-12-28 4 B $2.85 $142,250 D/D 50,000 159,930 2.74     -
   Romano Kelly A Director   –       •      –    2022-12-02 4 B $3.29 $98,700 D/D 30,000 38,315 2.39     -
   Litton Mark James Chief Executive Officer   •       •      –    2022-11-18 4 A $2.74 $1,814 D/D 662 129,217     -
   Church Kevin Executive VP, Research   •       –      –    2022-11-18 4 A $2.74 $1,800 D/D 657 62,052     -
   Mileson Glenna Chief Financial Officer   •       –      –    2022-11-18 4 A $2.74 $2,091 D/D 763 109,930     -
   Moebius Hans Chief Medical Officer   •       –      –    2022-11-15 4 B $3.29 $16,442 D/D 5,000 65,836 2.74     -
   Church Kevin Executive VP, Research   •       –      –    2022-10-28 4 OE $1.35 $4,995 D/D 3,700 61,395     -
   Moebius Hans Chief Medical Officer   •       –      –    2022-10-13 4 OE $1.35 $10,639 D/D 7,881 60,836     -
   Edelman Joseph Director   –       •       •   2022-06-30 4 B $2.99 $3,293,072 I/I 1,101,362 4,797,278 2.25     -
   Edelman Joseph Director   –       •       •   2022-06-29 4 B $2.99 $807,300 I/I 270,000 3,695,916 2.25     -
   Moebius Hans Chief Medical Officer   •       –      –    2022-06-28 4 B $2.88 $28,800 D/D 10,000 52,955 2.74     -
   Church Kevin Executive VP, Research   •       –      –    2022-06-23 4 S $2.69 $7,032 D/D (2,614) 57,695     -
   Litton Mark James Chief Executive Officer   •       •      –    2022-06-23 4 S $2.69 $21,412 D/D (7,960) 128,555     -
   Mileson Glenna Chief Financial Officer   •       –      –    2022-06-23 4 S $2.69 $7,032 D/D (2,614) 109,167     -
   Lenington Rachel Chief Operating Officer   •       –      –    2022-06-23 4 S $2.69 $11,279 D/D (4,193) 5,807     -
   Worthington Mark General Counsel   •       –      –    2022-06-23 4 S $2.69 $7,032 D/D (2,614) 19,097     -
   Moebius Hans Chief Medical Officer   •       –      –    2022-06-22 4 A $0.00 $0 D/D 10,000 42,955     -
   Church Kevin Executive VP, Research   •       –      –    2022-06-22 4 A $0.00 $0 D/D 10,000 60,309     -
   Litton Mark James Chief Executive Officer   •       •      –    2022-06-22 4 A $0.00 $0 D/D 20,000 136,515     -
   Mileson Glenna Chief Financial Officer   •       –      –    2022-06-22 4 A $0.00 $0 D/D 10,000 111,781     -
   Lenington Rachel Chief Operating Officer   •       –      –    2022-06-22 4 A $0.00 $0 D/D 10,000 10,000     -
   Worthington Mark General Counsel   •       –      –    2022-06-22 4 A $0.00 $0 D/D 10,000 21,711     -
  96 Records found
  1  2  3  4   
  Page 2 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us